How Belite Bio, a small, under-the-radar drugmaker, emerged as one of biotech's best performing IPOs
BioPharma
Source: biopharmadive.com
📰 Lin Bioscience News
Lin Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lin Bioscience. Real-time updates on events, politics, business and more.
Belite Bio stock soars 65% in wake of strong IPO performance
Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering
Source: seekingalpha.com
HilleVax's IPO hauls in $200M for clinical test of VLP norovirus vaccine from Takeda
Takeda Pharmaceutical spinout HilleVax broke the biotech IPO drought with a $200 million stock market debut for clinical development of a norovirus vaccine. Two eye health companies marked the other IPO activity: Belite Bio went public while Bausch + Lomb set financial terms for what could become one of the biggest IPOs of the year.
Source: medcitynews.com
Eye drug developer Belite Bio stock soars 160% following $36M IPO
Eye drug developer Belite Bio (BLTE) stock soared 160% following its $36M initial public offering. Shares of BLTE opened at $12.50 after pricing at $6 per American Depositary Share
United States Belite Bio Lin Bioscience Donovan Jones Belite Bio Antibiotics In Laboratory Research Scientist
Source: seekingalpha.com
Belite Bio Begins IPO Effort To Advance Eye Disease Treatments (Pending:BLTE)
Belite Bio has filed to raise an undisclosed amount in an IPO. The firm is developing treatment candidates for eye diseases. Read more about BLTE's IPO here.
Source: seekingalpha.com
Advancing a Treatment for a Common Eye Disease That Lacks One
The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program offers researchers a sm
Source: newswise.com
IVERIC bio : Risk Factors of IVERIC bio, Inc - Form 8-K
Exhibit 99.1 Risk Factors The following risk factors should be carefully considered together with all of the other information in our annual and quarterly... | October 21, 2021
Source: marketscreener.com
Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor Market – Industry Witness Huge Growth with Top 10 Key players |Lin Bioscience, Takeda Oncology, Nerviano Medical Sciences – KSU
Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor Market research is the entire portrayal of the exact information on the industry, market
United States Lin Bioscience Cell Division Cycle Segmented Research Nerviano Medical Sciences Related Protein Kinase Inhibitor Market
Source: ksusentinel.com